SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by
Growth Capitalist (https://growthcapitalist.com/2018/06/eidos-therapeutics-announces-pricing-of-initial-public-offering/)
SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by